Applied DNA Sciences Inc
APDN5.400USD
-0.109-2.00%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
34.19MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Applied DNA Sciences Inc Unternehmen
Applied DNA Sciences, Inc. is a biotechnology company. The Company is engaged in developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Company operates through three segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. Therapeutic DNA Production Services segment operations consist of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of messenger RNA (mRNA) therapeutics. MDx Testing Service segment operations consist of performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. DNA Tagging and Security Products and Services segment operations consist of the manufacture and detection of DNA for industrial supply chains and security services.
Unternehmensinformationen
Unternehmens-codeAPDN
Name des UnternehmensApplied DNA Sciences Inc
IPO-datumAug 24, 2001
Gegründet am2008
CEODr. James A. Hayward, Ph.D.
Anzahl der mitarbeiter46
WertpapierartOrdinary Share
GeschäftsjahresendeAug 24
Addresse50 Health Sciences Drive
StadtSTONY BROOK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl11790
Telefon16312408800
Websitehttps://adnas.com/
Unternehmens-codeAPDN
IPO-datumAug 24, 2001
Gegründet am2008
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. James A. Hayward, Ph.D.
Dr. James A. Hayward, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
9.00
--
Ms. Beth M. Jantzen
Ms. Beth M. Jantzen
Chief Financial Officer
Chief Financial Officer
3.00
--
Ms. Judith Murrah
Ms. Judith Murrah
President
President
3.00
--
Mr. Robert B. (Bob) Catell
Mr. Robert B. (Bob) Catell
Independent Director
Independent Director
2.00
--
Dr. Yacov A. Shamash, Ph.D.
Dr. Yacov A. Shamash, Ph.D.
Independent Director
Independent Director
2.00
--
Mr. Joseph D. Ceccoli
Mr. Joseph D. Ceccoli
Independent Director
Independent Director
1.00
--
Ms. Elizabeth M. Schmalz Shaheen
Ms. Elizabeth M. Schmalz Shaheen
Independent Director
Independent Director
--
--
Mr. Sanford (Sandy) Simon
Mr. Sanford (Sandy) Simon
Independent Director
Independent Director
--
--
Mr. Sanjay M. Hurry
Mr. Sanjay M. Hurry
Executive Director - Investor Relations and Corporate Communications
Executive Director - Investor Relations and Corporate Communications
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. James A. Hayward, Ph.D.
Dr. James A. Hayward, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
9.00
--
Ms. Beth M. Jantzen
Ms. Beth M. Jantzen
Chief Financial Officer
Chief Financial Officer
3.00
--
Ms. Judith Murrah
Ms. Judith Murrah
President
President
3.00
--
Mr. Robert B. (Bob) Catell
Mr. Robert B. (Bob) Catell
Independent Director
Independent Director
2.00
--
Dr. Yacov A. Shamash, Ph.D.
Dr. Yacov A. Shamash, Ph.D.
Independent Director
Independent Director
2.00
--
Mr. Joseph D. Ceccoli
Mr. Joseph D. Ceccoli
Independent Director
Independent Director
1.00
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product and authentication services - Supply chain
722.85K
60.41%
Clinical laboratory testing services (over-time)
324.58K
27.12%
Research and development services
147.44K
12.32%
Clinical laboratory testing services (point-in-time)
1.75K
0.15%
Product and authentication services - Large scale DNA production
0.00
0.00%
Product and authentication services - Asset marking
0.00
0.00%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product and authentication services - Supply chain
722.85K
60.41%
Clinical laboratory testing services (over-time)
324.58K
27.12%
Research and development services
147.44K
12.32%
Clinical laboratory testing services (point-in-time)
1.75K
0.15%
Product and authentication services - Large scale DNA production
0.00
0.00%
Product and authentication services - Asset marking
0.00
0.00%
Aktionäre
Update-Zeit: Sat, May 17
Update-Zeit: Sat, May 17
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Sabby Management, LLC
1.34%
Altium Capital Management LP
1.25%
S.H.N. Financial Investments Ltd
0.97%
Bigger (Michael)
0.96%
Anson Funds Management LP.
0.88%
Other
94.60%
Aktionärsstatistik
Aktionäre
Anteil
Sabby Management, LLC
1.34%
Altium Capital Management LP
1.25%
S.H.N. Financial Investments Ltd
0.97%
Bigger (Michael)
0.96%
Anson Funds Management LP.
0.88%
Other
94.60%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
2.60%
Corporation
1.77%
Individual Investor
0.99%
Hedge Fund
0.89%
Investment Advisor
0.61%
Research Firm
0.03%
Other
93.12%
Institutionelle Beteiligung
Update-Zeit: Mon, Feb 24
Update-Zeit: Mon, Feb 24
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
80
522.82K
38.02%
+37.07K
2024Q4
79
25.60M
46.39%
+1.44M
2024Q3
74
1.08M
9.78%
+703.30K
2024Q2
73
1.19M
10.83%
+424.27K
2024Q1
67
243.32K
209.10%
+86.27K
2023Q4
64
96.98K
13.46%
-84.74K
2023Q3
66
149.12K
21.28%
-82.31K
2023Q2
68
142.47K
21.43%
-74.27K
2023Q1
68
128.77K
20.06%
-84.88K
2022Q4
70
110.09K
17.17%
-81.02K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Sabby Management, LLC
104.48K
9.47%
+19.29K
+22.64%
Dec 31, 2024
Altium Capital Management LP
97.55K
8.84%
--
--
Dec 12, 2024
S.H.N. Financial Investments Ltd
75.50K
6.84%
--
--
Dec 12, 2024
Bigger (Michael)
75.00K
6.79%
--
--
Dec 12, 2024
Anson Funds Management LP.
68.51K
6.21%
--
--
Dec 12, 2024
L1 Capital Global Opportunities Master Fund Ltd.
62.50K
5.66%
--
--
Dec 12, 2024
Grossman (Bruce)
1.67K
0.15%
+1.67K
--
Feb 02, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: 11 hours ago
Update-Zeit: 11 hours ago
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Datum
Art
Verhältnis
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
